Latest posts 5
And if the clinical training, first-in-human trials, and awesome collaborative spirit aren’t enough, pretty sure we are the only program with a “Vascular Dogtor” on the team!
🚨Shape the future of Vascular Medicine. Train at Stanford alongside @NickLeeper78, @EriFukayaMD, @AHAthavale, & fabulous VS team @StanfordVascView quoted post on X
Complex vascular care
Cutting-edge research
Exceptional mentorship
Endless opportunities to innovate
Apply👇
vascular.stanford.edu/education/vasc…
Wow, awesome news Javid! As you know, Ricky is one of the brightest and most talented scientists that has ever come through my lab. And probably the nicest guy you could ever meet. Skys the limit for @ScientistBaylis! Cant wait to see what you two discover together.
Huge congrats to @ScientistBaylis! Ricky is a @lab_owens & @NickLeeper78 trained vascular biologist and now cardiology/#CardioOnc fellow at @UCSFCardiology! @MedicineUVA @ChrisKramerMD @UVaMSTP @mghmedres @immunox @UCSFMedicine @LabMcnamara @UCSF_CVfellows @AHAScienceView quoted post on X
Very fun collaborating on this piece with you Cam. Was great to learn about these important models as our lab ventures into environmental exposures, and especially the role of microplastics in atherosclerosis.
Check out our review on modeling the exposome in murine cardiovascular disease! We need to expand holistic whole organism models to study lifestyle and environmental impacts on health to identify evolutionarily selected inter-organ mechanisms that can be therapeutically harnessedView quoted post on X
Totally agree. Amazing to see so many of the key atherogenic lipids wiped out simultaneously. And fun to think of all the opportunities a dual targeting platform provides. siRNA-based “polypills”!
I’m very excited about these dimer data from @ArrowheadPharma!View quoted post on X
There’s a very exciting future for bispecific RNAi, further expanding the patient impact of this modality!